A Waistline Predicted a Leaking Brain | The Angry Gut, Chapter 12

Blood-brain barrier dysfunction · screening

Blood-Brain Barrier Dysfunction: Screening the Metabolic Drivers

Blood-brain barrier dysfunction is leakage across the brain’s barrier, and it appears before inflammatory markers move: in mild impairment a pericyte injury marker was 115% higher while spinal fluid cytokines were unchanged. Screening it means documenting the correlates primary care already owns: diabetes and adiposity.

The best-replicated barrier data point at insulin load and endothelial strain, not amyloid. That moves the actionable part of a memory workup into primary care.

A patient with a borderline cognitive screen is usually scheduled for a repeat in twelve months. Blood-brain barrier dysfunction, measured in living humans, is already present before that screen fails, and its best-documented correlates are diabetes, adiposity and endothelial strain: variables a primary care chart already tracks, or should.

The video A Waistline Predicted a Leaking Brain, from The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, walks through the imaging and spinal fluid record. The screening question it raises is practical. Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service that returns findings to the ordering physician; it does not diagnose or treat, and it does not measure barrier permeability. What it can document is the metabolic, vascular and cognitive terrain the permeability literature keeps implicating.

How is blood-brain barrier leakage measured, and how strong is the evidence?

Dynamic contrast MRI changed the model. Cognitively normal older adults showed hippocampal permeability 41% above young controls, 107% in CA1 and 48% in the dentate gyrus; in mild cognitive impairment the same regions rose by 24%, 53% and 27% over age-matched controls (Montagne et al., 2015). The same series found the reverse map in multiple sclerosis, with white matter changes of 32%, 26% and 23% and no hippocampal change, which argues the method is regionally specific rather than noisy.

In 245 participants imaged and 350 with spinal fluid, cognitively normal APOE4 carriers already had hippocampal and parahippocampal breakdown with no difference in amyloid or tau tracer uptake, and baseline pericyte injury predicted decline only in carriers (Montagne et al., 2020). Grade this correctly: these papers come from one group with overlapping cohorts. It is a deepening record, not independent replication, and the practice position is built on it with that label attached.

Does blood-brain barrier leakage appear before inflammation?

The underused result is temporal. In the 2015 cohort, spinal fluid cytokines (among them interleukin-6 and TNF-alpha), soluble adhesion molecules, tau and amyloid species showed no change, while soluble PDGFR-beta, a pericyte injury marker, was 115% higher in mild impairment and the albumin ratio was 30% higher. The 2019 follow-up in 161 people found no impaired-versus-unimpaired difference across 20 glial, inflammatory and degeneration biomarkers, while barrier measures still added predictive weight once amyloid and tau were in the model (Nation et al., 2019). Its enrollment deliberately left out vascular dementia and substantial cerebrovascular pathology, which partly manufactures the apparent independence from vascular risk.

The management implication is uncomfortable. A normal inflammatory panel in a patient with a memory complaint is not reassurance about the barrier. If leakage precedes the inflammatory signal, an anti-inflammatory strategy arrives late by design, and the earlier lever is whatever load is opening the door.

What causes blood-brain barrier dysfunction?

The CSF-to-serum albumin ratio, in 1,015 people, was unchanged in preclinical and prodromal Alzheimer’s disease, did not track amyloid PET or APOE genotype, and was elevated in diabetes, correlating with VEGF, ICAM-1 and VCAM-1 (Janelidze et al., 2017). In the healthy elderly arm, higher body mass index and waist-hip ratio predicted a raised ratio two decades later. Across 1,861 dementia patients, the ratio followed neurofilament light rather than Alzheimer’s biomarkers (Skillbäck et al., 2017). In type 2 diabetes, white matter permeability was raised before small vessel disease was visible on conventional imaging, independent of recent glycemic control, in a small sample of 25 patients against 12 controls (Chen et al., 2022).

Two biological drivers, then: chronic hyperinsulinemia and glucose load, the core of metaflammation, and endothelial dysfunction downstream of it. The third is structural. Memory complaints route to neurology, bowel complaints to gastroenterology, and waist circumference to no one, while the food environment keeps loading the variable nobody records. A postmortem series in CADASIL, 12 patients and 10 controls, found white matter lesion leakage inconsistent (Rajani et al., 2019), a reminder that not every hyperintensity implies an open barrier.

Who should be tested for blood-brain barrier dysfunction?

Reasonable selection criteria, consistent with Measura’s clinical selection page, include adults with a memory complaint or borderline screen plus one or more of the following:

Type 2 diabetes, prediabetes or suspected insulin resistance with a normal-appearing glucose history.
Central adiposity, or a BMI that underestimates fat mass.
Long-standing constipation. In 462,327 adults, constipation came before the combined outcome of stroke, dementia or Parkinson’s disease (adjusted HR 1.35), and dementia risk alone was 50% higher (Yun et al., 2025), strongest in the first two years, which also fits reverse causation.
Microbleeds on existing imaging in a diabetic patient. Of 4,500 candidate classification criteria tested, microbleeds were among only six that separated permeability.
Severe periodontitis, which in a national cohort of 10,115 matched pairs carried a hazard ratio of 1.24 for vascular dementia.

Can Measura measure blood-brain barrier dysfunction?

Permeability itself belongs to research imaging and CSF studies, and those two methods disagree in early disease. Stool calprotectin, which the chapter uses to ask whether the first brain is inflamed, is a separate test done elsewhere. Within the protocol, four measurements map onto the drivers:

Cognitive assessment converts a borderline screen into a documented baseline with a defined re-test interval, which pairs naturally with fall-risk evaluation.
Bioimpedance body composition separates fat mass from lean mass where BMI conflates them.
Laboratory panels quantify fasting insulin and glycemic markers.
Arterial stiffness and endothelial function gives a systemic vascular reading. It is not a cerebral measurement, and it should not be reported as one.

What a finding changes: a patient with a documented cognitive baseline, excess fat mass and hyperinsulinemia now has a measurable target and a re-measure date instead of a year of watchful waiting. The levers are nutrition, meal timing, sleep and activity; no intervention trial has yet shown that lowering waist circumference and fasting insulin reduces hippocampal permeability, and the mechanism tier is stated as such. The insulin side of the dementia argument is developed in insulin resistance and dementia screening.

Documentation and workflow

The annual wellness visit already carries a cognitive component, which makes it the natural encounter for recording body composition and metabolic values beside the cognitive result; see annual wellness visit integration. A standing order triggered by a borderline screen plus a metabolic criterion removes the dependence on individual recall. The primary care screening sequence is in cognitive screening in primary care, the patient-facing version is here, and the study-by-study limits are in the Chapter 12 Deep Dive. The next physician piece covers autonomic measurement in psychogastroenterology.

Frequently asked questions

Can blood-brain barrier dysfunction be measured in routine practice?

Not directly. Dynamic contrast MRI and the CSF-to-serum albumin ratio are research tools, and they diverge in early Alzheimer’s disease, where imaging detects hippocampal leakage and the albumin ratio does not move. Routine practice can document the correlates instead: glycemic and insulin status, fat mass, vascular function and a cognitive baseline. See how Measura results are reported.

Does a normal inflammatory panel argue against barrier dysfunction?

No. In the imaging cohort, CSF cytokines and adhesion molecules were unchanged while a pericyte injury marker rose 115% in mild impairment. A later study of 161 people found no differences across 20 inflammatory and degeneration biomarkers, yet barrier measures still predicted impairment. Leakage appears to precede the inflammatory signal. Read the clinical rationale for the protocol.

Which diabetic patients merit a cognitive baseline?

Permeability in type 2 diabetes was raised before small vessel disease appeared on conventional imaging and was independent of recent glycemic control, so a good A1c does not exclude the process. Patients with memory complaints, microbleeds on prior imaging, or central adiposity are practical starting points, with results documented for repeat comparison. See specialty applications by practice type.

Should the gingipain hypothesis change screening?

Not as a drug target. A gingipain inhibitor in 643 patients with mild to moderate Alzheimer’s disease missed both co-primary endpoints and was discontinued after liver enzyme elevations. Severe periodontitis remains a treatable inflammatory load, and its association was stronger for vascular than Alzheimer dementia, so dental referral belongs in the workup. Read about between-visit monitoring.

How should these findings be documented for quality reporting?

Record the cognitive result, body composition and metabolic values at the same encounter, with the selection criterion that triggered testing and a planned re-measure date. That structure supports quality measures and makes change over time interpretable rather than anecdotal. Findings describe risk terrain; they do not establish a dementia diagnosis. See MIPS and quality reporting guidance.

What are the symptoms of a damaged blood-brain barrier?

Early on, there may be none you can feel. On dynamic contrast MRI, leakage in the brain’s memory center was already present in mild cognitive impairment, and in APOE4 carriers whose thinking still tested normal. So the first sign is often only a memory complaint or a borderline cognitive screen. That is why a borderline result deserves a documented baseline now, not a repeat screen in twelve months.

Can a damaged blood-brain barrier be repaired?

The earlier lever is whatever load is opening the door: high insulin, glucose load and strain on the lining of blood vessels. An anti-inflammatory approach arrives late, because leakage shows up before the inflammatory signal does. We state the limit plainly: no intervention trial has yet shown that lowering waist size and fasting insulin reduces leakage in the hippocampus. What can be done now is measure those drivers and re-measure them.

How can I repair my blood-brain barrier naturally?

Work on the load, not the leak. The drivers tied most closely to barrier leakage are high insulin, glucose load, excess body fat and strain on blood vessels. The levers for those are nutrition, meal timing, sleep and activity. Measure fasting insulin, body composition and a cognitive baseline first, then re-measure on a set date, so any change is documented instead of guessed.

See how the protocol fits a memory workup

Learn how Measura cognitive, body composition and metabolic testing can sit inside an existing annual wellness visit or memory workflow.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., Harrington, M. G., Chui, H. C., Law, M., & Zlokovic, B. V. (2015). Blood-brain barrier breakdown in the aging human hippocampus. Neuron, 85(2), 296-302. https://doi.org/10.1016/j.neuron.2014.12.032
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., Buennagel, D. P., Harrington, M. G., Benzinger, T. L. S., Fagan, A. M., Ringman, J. M., Schneider, L. S., Morris, J. C., Reiman, E. M., Caselli, R. J., … Zlokovic, B. V. (2020). APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature, 581(7806), 71-76. https://doi.org/10.1038/s41586-020-2247-3
Nation, D. A., Sweeney, M. D., Montagne, A., Sagare, A. P., D’Orazio, L. M., Pachicano, M., Sepehrband, F., Nelson, A. R., Buennagel, D. P., Harrington, M. G., Benzinger, T. L. S., Fagan, A. M., Ringman, J. M., Schneider, L. S., Morris, J. C., Chui, H. C., Law, M., Toga, A. W., & Zlokovic, B. V. (2019). Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nature Medicine, 25(2), 270-276. https://doi.org/10.1038/s41591-018-0297-y
Janelidze, S., Hertze, J., Nägga, K., Nilsson, K., Nilsson, C., Wennström, M., van Westen, D., Blennow, K., Zetterberg, H., & Hansson, O. (2017). Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiology of Aging, 51, 104-112. https://doi.org/10.1016/j.neurobiolaging.2016.11.017
Skillbäck, T., Delsing, L., Synnergren, J., Mattsson, N., Janelidze, S., Nägga, K., Kilander, L., Hicks, R., Wimo, A., Winblad, B., Hansson, O., Blennow, K., Eriksdotter, M., & Zetterberg, H. (2017). CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiology of Aging, 59, 1-9. https://doi.org/10.1016/j.neurobiolaging.2017.06.028
Chen, Y. C., Lu, B. Z., Shu, Y. C., & Sun, Y. T. (2022). Spatiotemporal dynamics of cerebral vascular permeability in type 2 diabetes-related cerebral microangiopathy. Frontiers in Endocrinology, 12, 805637. https://doi.org/10.3389/fendo.2021.805637
Rajani, R. M., Ratelade, J., Domenga-Denier, V., Hase, Y., Kalimo, H., Kalaria, R. N., & Joutel, A. (2019). Blood brain barrier leakage is not a consistent feature of white matter lesions in CADASIL. Acta Neuropathologica Communications, 7(1), 187. https://doi.org/10.1186/s40478-019-0844-x
Yun, Q., Wang, S., Li, B., Yang, Z., Wei, C., Yuan, J., Hu, J., Li, Y., Yang, Z., Sha, F., & Tang, J. (2025). Constipation preceding stroke, dementia and Parkinson’s disease in middle-aged and older adults: a population-based cohort study. Age and Ageing, 54(9), afaf257. https://doi.org/10.1093/ageing/afaf257
Kim, D. H., Jeong, S. N., & Lee, J. H. (2020). Severe periodontitis with tooth loss as a modifiable risk factor for the development of Alzheimer, vascular, and mixed dementia: National Health Insurance Service-National Health Screening Retrospective Cohort 2002-2015. Journal of Periodontal & Implant Science, 50(5), 303-312. https://doi.org/10.5051/jpis.2000600030
Cortexyme, Inc. (sponsor). ClinicalTrials.gov registry record NCT03823404. (2022). GAIN Trial: A randomized, double-blind, placebo-controlled study of COR388 in subjects with Alzheimer’s disease. https://clinicaltrials.gov/study/NCT03823404